• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Verily

FDA clears iRhythm’s ZEUS system for Zio Watch

July 22, 2022 By Sean Whooley

iRhythm Technologies (Nasdaq:IRTC) announced today that it received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) system. ZEUS, produced in partnership with Google’s life sciences sister company Verily, combines deep-learned algorithms with iRhythm’s cardiac arrhythmia service, providing the AI algorithm component for the Zio Watch sensor-based wearable for non-invasive, clinical-grade, long-term continuous monitoring […]

Filed Under: Business/Financial News, Cardiovascular, Diagnostics, Featured, Health Technology, News Well, Patient Monitoring, Software / IT Tagged With: Google, iRhythm Technologies, Verily

iRhythm plans silent AFib screening pilots, high-level hires and Zio Watch evaluations

January 24, 2022 By Jim Hammerand

iRhythm Technologies (NSDQ:IRTC) has big plans for 2022 and its remote external electrocardiogram monitors as the medical device developer gears up for growth. President and CEO Quentin Blackford is looking to hire an international general manager among other roles in the coming months, he told Medical Design & Outsourcing after presenting at this month’s 2022 J.P. Morgan Healthcare Conference, […]

Filed Under: Big Data, Blog, Cardiovascular, Diagnostics, Digital Health, Featured, Health Technology, News Well, Patient Monitoring Tagged With: Alphabet (Google), Google, iRhythm Technologies Inc., Verily

FDA rejects Verily’s smartwatch-based Parkinson’s exam

June 14, 2021 By Sean Whooley

The FDA issued a letter to Google’s (NSDQ:GOOGL) Verily declaring that it will not accept a letter of intent for the company’s Parkinson’s exam. Verily submitted the LOI for drug development tool (DDT) for the virtual motor exam for Parkinson’s disease. The device measures a change in digitally assessed parameters of a subset of Parkinson’s disease […]

Filed Under: Diagnostics, Digital Health, Featured, Food & Drug Administration (FDA), Health Technology, Neurological, Patient Monitoring, Regulatory/Compliance, Software / IT Tagged With: FDA, Parkinson's disease, Verily

FDA grants Verily EUA for pooled COVID-19 testing

September 9, 2020 By Sean Whooley

The FDA has granted Google’s (NSDQ:GOOGL) Verily emergency use authorization (EUA) for its pooled COVID-19 testing. In a letter to the company dated yesterday, the FDA confirmed the EUA status for the qualitative test for detecting nucleic acid from SARS-CoV-2 in respiratory specimens procured through nasal, mid-turbinate, nasopharyngeal and oropharyngeal swabbing. The test also can be […]

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: coronavirus, COVID-19, FDA, Verily

Verily launches clinical lab for COVID-19 testing

August 12, 2020 By Sean Whooley

Google’s (NSDQ:GOOGL) Verily announced that it established a CLIA-certified lab to create additional lab capacity to support COVID-19 testing. The lab, at Verily’s San Francisco headquarters, is designed to support programs in the COVID-19 testing space as demand continues to increase while the pandemic goes on, including the company’s own return-to-work efforts for its own employees, […]

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics Tagged With: coronavirus, COVID-19, Verily

LivaNova adds Verily to depression study

February 27, 2020 By Sean Whooley

LivaNova (NSDQ:LIVN) announced that it has added Google’s (NSDQ:GOOGL) Verily to its study of vagus nerve stimulation (VNS) therapy for difficult-to-treat depression (DTD). The Recover clinical will gather quantitative data on patient behavior using Verily’s technology and analytics. The data could help the researchers understand depressive episodes and the patient’s response to treatment. Study participants will […]

Filed Under: Business/Financial News, Clinical Trials, Health Technology, Neuromodulation/Neurostimulation, Software / IT Tagged With: Alphabet (Google), LivaNova, Verily

Verily, Santen do a JV for ophthalmological devices

February 6, 2020 By Sean Whooley

Santen Pharmaceutical (OTC:SNPHY) and Verily, an Alphabet (NSDQ:GOOGL) company, announced that they are entering into a joint venture to focus on applying microelectronics and scalable digital technologies to ophthalmology. Osaka, Japan-based Santen and San Francisco-based Verily say they want to improve eye health globally. According to a news release, the joint venture is slated to combine […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Optical/Ophthalmic Tagged With: Alphabet (Google), Santen Pharmaceuticals, Verily

New 510(k) boosts iRhythm, Verily efforts for AFib screening

January 24, 2020 By Chris Newmarker

The latest 510(k) clearance for the Verily Study Watch will further the efforts of the Google sister company and iRhythm Technologies (NSDQ:IRTC)  to improve atrial fibrillation treatment. Verily — a life science company under Alphabet (NSDQ:GOOGL) — recently received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable. “We’ve worked carefully […]

Filed Under: 510(k), Business/Financial News, Cardiovascular, Clinical Trials, Diagnostics, Digital Health, Featured, Regulatory/Compliance, Software / IT Tagged With: Alphabet (Google), artificial intelligence, iRhythm Technologies Inc., Verily

FDA clears Verily Study Watch for additional capabilities

January 22, 2020 By Chris Newmarker

Verily, Google’s life science’s sister company under Alphabet (NSDQ:GOOGL), has received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable. The FDA announcement, last updated Jan. 20, did not include additional information. The agency cleared ECG capabilities on the Study Watch in January 2019. Launched in April 2017, the Study […]

Filed Under: 510(k), Clinical Trials, Digital Health, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pharmaceutical, Regulatory/Compliance Tagged With: Alphabet (Google), Novartis, Otsuka Holdings, Pfizer, Sanofi, Verily

Earlens to partner with Verily for next-gen Earlens hearing device

January 13, 2020 By Danielle Kirsh

Earlens today said it entered a strategic agreement with Verily to develop next-generation capabilities for the Earlens Contact Hearing Solution. Earlens’s Contact Hearing Solutions directly activates the hearing system to deliver the broadest bandwidth in a nonsurgical hearing solution. It uses a small lens to vibrate the eardrum to replicate the natural hearing process. “Unlike […]

Filed Under: Business/Financial News Tagged With: EarLens, Verily

Verily hires former Tesla executive as CFO

January 9, 2020 By Chris Newmarker

Verily — Google’s life sciences sister company under Alphabet (NSDQ:GOOG)  — has hired Tesla veteran Deepak Ahuja as its CFO, according to a report on CNBC. Ahuja previously served two stints as CFO at Tesla. He left Tesla in early 2019 and was serving as a senior advisor to Capricorn Investment Group, according to his LinkedIn […]

Filed Under: Business/Financial News, Diabetes, Digital Health, Featured, News Well Tagged With: Alphabet (Google), Personnel Moves, Verily

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy